<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosbruger, Timothy L</style></author><author><style face="normal" font="default" size="100%">Dinou, Amalia</style></author><author><style face="normal" font="default" size="100%">Duke, Jamie L</style></author><author><style face="normal" font="default" size="100%">Ferriola, Deborah</style></author><author><style face="normal" font="default" size="100%">Mehler, Hilary</style></author><author><style face="normal" font="default" size="100%">Pagkrati, Ioanna</style></author><author><style face="normal" font="default" size="100%">Damianos, Georgios</style></author><author><style face="normal" font="default" size="100%">Mbunwe, Eric</style></author><author><style face="normal" font="default" size="100%">Sarmady, Mahdi</style></author><author><style face="normal" font="default" size="100%">Lyratzakis, Ioannis</style></author><author><style face="normal" font="default" size="100%">Tishkoff, Sarah A</style></author><author><style face="normal" font="default" size="100%">Dinh, Anh</style></author><author><style face="normal" font="default" size="100%">Monos, Dimitri S</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for deceased donor expedited HLA typing.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Immunol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Immunol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Genotyping Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Histocompatibility Testing</style></keyword><keyword><style  face="normal" font="default" size="100%">HLA Antigens</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Nanopore Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Tissue Donors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 Aug</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">81</style></volume><pages><style face="normal" font="default" size="100%">413-422</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The comprehensive characterization of human leukocyte antigen (HLA) genomic sequences remains a challenging problem. Despite the significant advantages of next-generation sequencing (NGS) in the field of Immunogenetics, there has yet to be a single solution for unambiguous, accurate, simple, cost-effective, and timely genotyping necessary for all clinical applications. This report demonstrates the benefits of nanopore sequencing introduced by Oxford Nanopore Technologies (ONT) for HLA genotyping. Samples (n&amp;nbsp;=&amp;nbsp;120) previously characterized at high-resolution three-field (HR-3F) for 11 loci were assessed using ONT sequencing paired to a single-plex PCR protocol (Holotype) and to two multiplex protocols OmniType (Omixon) and NGSgo®-MX6-1 (GenDx). The results demonstrate the potential of nanopore sequencing for delivering accurate HR-3F typing with a simple, rapid, and cost-effective protocol. The protocol is applicable to time-sensitive applications, such as deceased donor typings, enabling better assessments of compatibility and epitope analysis. The technology also allows significantly shorter turnaround time for multiple samples at a lower cost. Overall, the nanopore technology appears to offer a significant advancement over current next-generation sequencing platforms as a single solution for all HLA genotyping needs.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><custom1><style face="normal" font="default" size="100%">&lt;p&gt;https://www.ncbi.nlm.nih.gov/pubmed/32595056?dopt=Abstract&lt;/p&gt;
</style></custom1></record></records></xml>